MBD2 and neoplasm: KDM6A, a member of the COMPASS-like complex, possesses demethylase activity that counteracts the PRC2 complex by demethylating H3K27me3 and facilitating H3K4me, thereby enhancing IFN responses and tumor-suppressive gene expression [141].